Pain Response to Cannabidiol in Opioid-induced Hyperalgesia, Acute Nociceptive Pain and Allodynia By Using a Model Mimicking Acute Pain in Healthy Adults

• Status: Completed
• Trial end date: 2020-10-15
• Target enrollment: 0
• Participant gender: All

Summary

Prospective, randomized, placebo-controlled, double-blinded, crossover study to investigate the effect of cannabidiol (CBD) on remifentanil-induced hyperalgesia in healthy volunteers in a well-established acute pain model. Participants are randomized according to the order of the two treatments (CBD + Remifentanil or Placebo + Remifentanil).

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospital, Basel, Switzerland
• Treatments: Epidiolex; Remifentanil

Criteria

Inclusion Criteria:

• BMI between 18.5 until 25 kg/m2

• Able to give informed consent

Exclusion Criteria:

• Regular consumption of cannabinoids or other drugs / substances

• Regular intake of medications potentially interfering with pain sensation (analgesics, antihistamines, calcium and potassium channel blockers, serotonin / noradrenaline reuptake inhibitors, corticosteroids)

• Neuropathy

• Chronic pain

• Neuromuscular disease

• Psychiatric disease

• Known or suspected kidney or liver disease

• Pregnancy (cf. 8.6 Trial specific preventive measures) / Lactation

• Allergy / hypersensitivity to cannabidiol

• Contraindications for Remifentanil (e.g. hypersensitivity)